ST. JOSEPH, Mich., July 17 /PRNewswire/ -- GeneGo, Inc., the leading provider of databases, software and services in systems biology, today announced the appointment of Dr. Richard Brennan as Director of Toxicology. Dr. Brennan is a Diplomate of the American Board of Toxicology and brings extensive experience in the pharmaceutical and biotechnology industry, with particular expertise in molecular toxicology and toxicogenomics. Dr. Brennan will lead the MetaTox Consortium, a joint industry and government effort focused on development of systems biology tools for prediction of human toxicity of new compounds. Dr. Brennan's previous position was Director of Molecular and Investigative Toxicology at Iconix Biosciences, where he was a member of the team that delivered ToxFX(TM), a toxicogenomics data management and analysis solution. Before that, Dr. Brennan was an Associate Director of Pharmacology and Cell Biology at Cornerstone Pharmaceuticals (Stony Brook, NY) and as Senior Scientist at OSI Pharmaceuticals (Farmingdale, NY). Dr. Brennan holds a Ph.D. in Chemistry from the University of Warwick, UK, and conducted post-doctoral research at the University of Manchester and at the Harvard School of Public Health before joining industry.
"We welcome Richard to GeneGo team", said Tatiana Nikolskaya, GeneGo's founder and CSO. "At this point, the field of mammalian systems biology is getting diversified in specific application areas, such as common human diseases, drug safety and medicinal chemistry. Development of next generation products in these areas requires leaders with solid domain expertise, and Richard is both a Board certified expert toxicologist and a developer of systems analysis tools. The MetaTox project, partially supported by our NIEHS Phase II grant, will include toxicity ontologies, signature networks and functional descriptors models for different types of toxicity, as well as manual annotation of toxicity relevant pathways in human, rat, mouse and in vitro models."
About GeneGo
GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.3(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.3(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com.
MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM), MetaMiner(TM), and 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.
GeneGo, Inc.CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo,Inc., +1-858-756-7996, julie@genego.com
Web site: http://www.genego.com/
